Icon Plc $ICLR Shares Purchased by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC boosted its holdings in Icon Plc (NASDAQ:ICLR) by 13.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 66,507 shares of the medical research company’s stock after buying an additional 7,778 shares during the period. Motley Fool Wealth Management LLC’s holdings in Icon were worth $9,674,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new stake in Icon in the 1st quarter worth about $28,000. Ameritas Advisory Services LLC acquired a new stake in Icon in the 2nd quarter worth about $48,000. LRI Investments LLC acquired a new stake in Icon in the 2nd quarter worth about $49,000. Blue Trust Inc. boosted its stake in Icon by 44.0% in the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after buying an additional 120 shares during the last quarter. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in Icon in the 1st quarter worth about $69,000. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on ICLR shares. Truist Financial raised their price target on Icon from $187.00 to $234.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Evercore ISI raised their price target on Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Leerink Partners set a $220.00 price objective on Icon in a report on Thursday. Mizuho raised their price objective on Icon from $173.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Finally, Rothschild Redb upgraded Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $207.14.

Icon Stock Performance

Icon stock opened at $182.03 on Tuesday. The stock’s 50-day moving average is $178.77 and its 200-day moving average is $158.76. The company has a market cap of $14.70 billion, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 2.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. Icon Plc has a 12 month low of $125.10 and a 12 month high of $234.60.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $3.31 EPS for the quarter, beating the consensus estimate of $3.28 by $0.03. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The company’s revenue was up .6% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. Equities analysts anticipate that Icon Plc will post 13.38 earnings per share for the current year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.